Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-072 combination study in adults with solid tumors
2019-000999-42Phase 2Terminated
- Sponsor
- CytomX
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pacmilimab and ipilimumab in Nonhematologic neoplasms and cancer, sponsored by CytomX. Primary endpoint: Objective response rate. Started Jun 2019; status: terminated.
02
Drugs
pacmilimabipilimumab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2019-000999-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000999-42.